Skip to main content

The Road to Cures Through Immunotherapy and Precision Medicine

Click Here to Participate 

CME Activity Release Date: March 10, 2022
CME Credit Valid Through: March 9, 2023 


Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.



This activity provides learners with an overview of the latest advancements in biology and treatments for acute myeloid leukemia, aggressive lymphoma, and myeloma. The development and practical applications for CAR T-cell therapy in blood cancers is presented. A review of data from The Leukemia & Lymphoma Society patient registry on SARS-CoV-2 vaccination and antibody response in patients with blood cancer provides a glimpse of unmet needs in this vulnerable patient population.



This activity is provided as a series of five modules:

  1. CAR-T Therapy: What’s in the CARds? – Module 1
  2. AML 2021: Strategies for Attack Before Diagnosis and After Remission – Module 2
  3. Efficacy of Targeted Therapy in Genetic Subtypes of Aggressive Lymphoma – Module 3
  4. Novel Therapeutic Strategies in Myeloma – Module 4
  5. COVID-19, Vaccinations, and Blood Cancer Patients: The LLS Registry and Q&A – Module 5


Credit Available

Physicians —AMA PRA Category 1 Credit(s)™    
All other healthcare professionals completing this course will be issued a statement of participation.



Jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.


Support Statement

Funding provided by The Leukemia & Lymphoma Society. No commercial support provided for this accredited continuing education activity.


For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at


< Back to Continuing Education